GREENVILLE, N.C., July 30, 2012 /PRNewswire-iReach/ -- Metrics Inc. today announced that it has launched a generic version of Oxycodone HCl 5 mg Capsules through its Midlothian division. The Abbreviated New Drug Application (ANDA) was granted to Coastal Pharmaceuticals by the U.S. Food and Drug Administration (FDA) on July 26th. Coastal Pharmaceuticals and Midlothian Laboratories are both divisions of Metrics Inc. This new product is AB-rated and is the first approved generic for the Reference Listed Drug (RLD) Oxycodone HCl 5 mg Capsules by Lehigh Valley Technologies Inc.
Metrics Inc. is a contract pharmaceutical development and manufacturing company that specializes in a broad spectrum of contract services to support investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions to regulatory agencies.
PR Newswire
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Midlothian Laboratories
